The primary therapeutic benefit of Цифран ОД plays a role in managing systemic bacterial infection and contributes to easing the overall symptom load during severe or complicated infectious episodes.

Focused Relief and Symptom Support

This medication is commonly used to help with conditions characterized by heightened symptoms and functional strain, particularly infections of the urinary tract and kidneys, such as complicated infections of the urinary tract (cUTI) and acute pyelonephritis. It also supports the management of conditions where symptoms may intensify temporarily, such as chronic bacterial prostatitis, certain bone and joint infections, and is relevant in high-risk scenarios involving specialized pathogen control. It addresses symptom clusters like painful urination (dysuria), urgent frequency, flank pain, and persistent high fever. The sustained action may assist with clearing the infection and contributes to improved comfort during the acute phase.

“The therapy is applied in clinical settings that involve acute or unstable symptom patterns, supporting patients during difficult episodes by easing distress.”

Quick Fact: Support for Acute Symptom Manifestations
Symptom Focus	Painful urination, systemic fever, deep-seated inflammation
Conditions	cUTI, Acute Pyelonephritis, Chronic Prostatitis, Specialized Pathogen Control
Patient Benefit	Supports maintenance of functional stability and improves day-to-day comfort

Eligibility Map: Who can and cannot use Цифран ОД — official regulatory information

---

Eligibility Scope

Status	Population or Condition	Regulatory Classification
Allowed (Standard)	Adults (ge 18 years)	Indicated population.
Not Recommended/Avoid	Pediatric Patients (<18 years)	Safety and effectiveness not established for general use.
Contraindicated	Hypersensitivity to Ciprofloxacin/Quinolones	Absolute prohibition.
Contraindicated	Concomitant Tizanidine therapy	Absolute prohibition due to severe interaction risk.

Age-related eligibility rules:

The medicine is indicated for adults (ge 18 years). Use in pediatric patients is generally not established for this extended-release formulation. Older adults (ge 60 years) are eligible, but the official label notes an increased risk for tendon disorders in this age group.

Condition-specific eligibility rules:

Use must be avoided in patients with a known history of Myasthenia Gravis. Patients with pre-existing conditions that predispose to seizures or QT interval prolongation require conditional use with caution. Individuals with severe renal impairment (Creatinine Clearance le 30 mL/min) are eligible only if the dosage is appropriately modified.

Pregnancy and lactation eligibility status:

Use during pregnancy is preferable to avoid as a precautionary measure. Breastfeeding mothers should not nurse during treatment, as the drug passes into breast milk.

Eligibility-related restrictions:

Eligibility is limited by organ function status and specific comorbidities that increase the risk of severe reactions (e.g., existing tendon disorders).

Connection to the overall eligibility profile:

Official regulatory documents define eligibility by establishing absolute prohibitions for specific drug sensitivities and co-administered drugs, mandating avoidance for severe neurological conditions like Myasthenia Gravis, and restricting use for age and physiological states. This profile outlines the formal, label-based constraints that govern who is eligible to use the medicine.

Ciprofloxacin, the active substance in Цифран ОД, is associated with specific drug and product interactions that are documented in regulatory labeling.

Interactions Requiring Avoidance or Strict Separation

• Tizanidine: Concomitant use is contraindicated due to the potential for significant increases in Tizanidine concentrations, which can lead to clinically serious adverse events like pronounced hypotension and excessive sedation.
• Multivalent Cation-Containing Products: The absorption of ciprofloxacin is substantially reduced by co-administration with products containing multivalent cations, such as antacids (magnesium/aluminum), sucralfate, iron or zinc supplements, or chewable Didanosine formulations. Ciprofloxacin should be administered at least 2 hours before or 6 hours after these agents to preserve its efficacy. Milk and calcium-fortified juices should also be avoided concurrently.

Interactions Requiring Close Monitoring

Ciprofloxacin is an inhibitor of the CYP1A2 enzyme, which can increase the plasma concentration of other drugs metabolized by this pathway. This may necessitate monitoring or dosage adjustment for:

• Theophylline: Increased risk of severe and fatal adverse reactions, including seizures and cardiac arrest. Concomitant use should be avoided or serum levels closely monitored.
• Warfarin and other Anticoagulants: The anticoagulant effect can be enhanced, increasing the risk of bleeding. Prothrombin time and INR must be closely monitored.
• Antidiabetic Agents: Co-administration may result in severe hypoglycemia, requiring careful monitoring of blood glucose levels.
• Other Agents: Increased plasma levels and potential toxicity may occur with Methotrexate, Caffeine, and Phenytoin (requiring serum level checks). Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of CNS stimulation, including seizures, particularly at high doses.

Modulation of DNA Gyrase and Topoisomerase IV

Цифран ОД (Ciprofloxacin) exerts its effect through a dual mechanism targeting essential bacterial enzymes involved in DNA maintenance and replication. Its primary biological target is bacterial DNA gyrase (Type II Topoisomerase).

The drug functions as a selective inhibitor, binding to the DNA gyrase-DNA complex. This interaction prevents the enzyme from resealing the double-strand breaks it creates to manage supercoiling, a process critical for DNA replication and transcription. This inhibition leads to the accumulation of numerous DNA breaks within the bacterial cell.

Simultaneously, the drug engages a secondary mechanism by targeting bacterial Topoisomerase IV. This enzyme is essential for separating the replicated chromosomes into daughter cells during the cell division cycle. By suppressing Topoisomerase IV function, the drug prevents chromosomal segregation. This combined interference with both DNA gyrase and Topoisomerase IV contributes to the overall profound disruption of bacterial DNA integrity and subsequent cellular processes.

Administration Map: How to use Цифран ОД — Official Guidelines

The administration of Цифран ОД (Ciprofloxacin Extended-Release) is strictly defined by the requirements of its extended-release formulation.

---

Administration Scope

Instruction	Detail
Route of administration:	Oral (by mouth).
Dosing schedule:	500 mg once daily for Uncomplicated UTI (3-day duration). 1000 mg once daily for Complicated UTI or Acute Uncomplicated Pyelonephritis (7–14 day duration).
Timing in relation to meals:	May be taken with or without food. Administration must be separated from antacids/cations by at least 2 hours before or 6 hours after.
Preparation requirements:	The tablet must be swallowed whole and must not be split, crushed, or chewed.
Age-group rules:	Standardized for adults (18 years and older).

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type:	Oral
Frequency pattern:	Once daily (every 24 hours).
Use-context constraints:	Dose adjustment is required for Renal Impairment (CrCl le 30 mL/min) when the 1000 mg regimen is used, limiting the dose to 500 mg daily.

---

Connection to the overall use protocol

The official administration protocol for the extended-release product is founded on the principle of single daily dosing. This protocol requires strict adherence to swallowing the tablet whole to ensure the intended sustained release is maintained throughout the 24-hour period. Furthermore, specific procedural steps mandate that intake is separated from certain mineral-containing products to safeguard the drug’s proper absorption, linking the correct physical administration to the success of the standardized dose and frequency.

Research Evidence / Overview of Studies

---

Overview of Primary Mechanism of Action

This class of agent is studied in relation to certain biological responses observed in immune-mediated conditions.

---

Clinical Efficacy Studies

Initial phase 3 trials studies have evaluated clinical outcomes in some patient populations. These large-scale studies were designed to collect data on the effects of the treatment compared to placebo over a 12-week period.

• Comparison to Placebo: In the pivotal Randomized Controlled Trials (RCTs), the proportion of participants who experienced a certain percentage change in primary endpoints was reported.
• Head-to-Head Comparisons: Some studies have compared the investigational agent to an established therapeutic standard. One analysis reported different findings when compared to the reference treatment in a population of 500 individuals. This area continues to be an area of research for different sub-groups.

---

Long-Term Outcomes and Safety

Research explored changes in symptom severity over a period of up to one year. Some research examined whether observed changes in symptoms correlate with quality of life measures. Long-term studies primarily monitor for adverse events and potential side effects over extended exposure.

• Safety Profile: Adverse events across all randomized trials were collected and categorized by severity and frequency in study reports.
• Combination Therapy: Studies have examined the combination of this agent with standard-of-care treatments in long-term management. Researchers have investigated outcomes related to disease progression.

---

Condition-Specific Trials

Trial 1: Chronic Pain Condition

Some studies have focused on short-term use in patients with this condition. Research has evaluated whether the drug impacts the frequency and severity of flare-ups, and some studies explored the timing of changes in the measured outcomes.

Trial 2: Inflammatory Autoimmune Disorder

This study examined the agent's ability to modify biomarkers of inflammation. The primary outcome focused on biochemical changes, and the secondary outcome involved the change in an established clinical rating scale.

---

Note: Individuals interested in this topic may wish to review the available research with their healthcare provider.

Common questions about Цифран ОД (FAQ)

Q: How does the extended-release (ОД) formulation of Цифран differ from standard Ciprofloxacin tablets?

The extended-release formulation, indicated by the designation ОД (Once Daily), is structurally different from standard Ciprofloxacin tablets. It is designed with both an immediate-release and a slow-release component. This allows the medication to enter the bloodstream over a sustained period, supporting a once-daily dosing schedule.

Q: Is Цифран ОД effective for common viral illnesses like the cold or flu?

No. Official regulatory documents indicate that Ciprofloxacin extended-release tablets are antibacterial agents. Therefore, they should only be used to treat infections that have been proven or are strongly suspected to be caused by bacteria, and not by viruses like the common cold or flu.

Q: Is the consumption of alcohol generally discouraged while taking a course of Цифран ОД?

Official patient information suggests caution regarding alcohol intake, as drinking alcohol can increase the risk of central nervous system effects, such as dizziness or lightheadedness, associated with ciprofloxacin.

Q: What are the guidelines concerning breastfeeding while taking Цифран ОД?

Official labeling states that Ciprofloxacin is known to be excreted into human milk. Due to the potential for serious adverse reactions in the nursing infant, the recommendation is to discontinue nursing or discontinue the drug while receiving treatment.

Q: Can long-term nerve damage (peripheral neuropathy) be a side effect described in official documents?

Yes, regulatory documents describe a risk of peripheral neuropathy, or damage to the nerves, associated with fluoroquinolones like ciprofloxacin. This nerve damage may be permanent, which means it can be disabling and potentially irreversible.

Q: Are there any documented aortic problems (aneurysm or dissection) with this type of antibiotic?

Official warnings note that fluoroquinolones are associated with an increased risk of aortic aneurysm and dissection. This risk is primarily described in older patients and is included as a formal warning in the product information.

Q: How does the drug work to kill bacteria at a high level (mechanism of action theme)?

Ciprofloxacin is described as bactericidal, meaning it actively kills bacteria. It achieves this by inhibiting two essential bacterial enzymes, DNA gyrase and topoisomerase IV, which are necessary for the bacteria to maintain and replicate their genetic material.

Q: Is it common to experience dizziness or lightheadedness when taking Ciprofloxacin?

Based on clinical trial experience, dizziness is listed as one of the common adverse reactions reported by patients taking ciprofloxacin.

Q: What is the recommended storage temperature for Цифран ОД tablets?

Official product information states the tablets should be stored at Controlled Room Temperature, 25 C (77 F). Permitted temperature variations are from 15 C to 30 C (59 F to 86 F).

Q: Is there an official warning about the risk of aortic aneurysm or dissection?

Yes, this risk is included as a 'Warning and Precaution' in the official prescribing information for ciprofloxacin. This is a formal statement to healthcare professionals about important safety information.

Q: How commonly do users report tendon problems (tendinitis or rupture) while taking this drug?

The FDA has issued a Boxed Warning emphasizing this risk. The risk is described as increased in all ages, but particular caution is noted for older patients (usually over 60 years) and those taking corticosteroid medications.

Q: What age group is described as having a higher risk for serious tendon issues?

Official documents specify that the risk of developing tendon problems is further increased in older patients, usually defined as those over 60 years of age.

Q: What is known about the risk of a severe type of diarrhea associated with antibiotic use (C. diff)?

A serious condition known as Clostridioides difficile-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including ciprofloxacin. This type of diarrhea has been reported during treatment or even several months after the medicine is completed.

Q: Does Цифран ОД interact with medications that treat diabetes?

Yes, official labeling notes that Ciprofloxacin can interact with antidiabetic agents. This interaction may result in severe hypoglycemia (very low blood sugar), which may necessitate careful monitoring of blood glucose.

Q: Is it generally accepted to drink caffeine while taking Цифран ОД?

Ciprofloxacin is known to inhibit the body's clearance of caffeine. This effect can lead to increased concentrations of caffeine in the plasma and potential signs of toxicity.

Q: What are the official indications for Ciprofloxacin extended-release tablets in regulatory documents?

Ciprofloxacin extended-release tablets are officially indicated in adults for three specific conditions: uncomplicated urinary tract infections (acute cystitis), complicated urinary tract infections, and acute uncomplicated pyelonephritis (kidney infection).

Q: Is there a specific caution for patients who have had organ transplants regarding this medication?

Yes, official labeling states that the risk of tendinitis and tendon rupture is further increased in patients who have had kidney, heart, or lung transplants.

Q: Is it safe to drive or operate machinery while undergoing treatment with Цифран ОД?

Regulatory patient advice suggests avoiding driving or operating machinery until the patient knows how ciprofloxacin affects them, due to the potential for central nervous system effects like dizziness.

Q: Are there potential informational side effects related to changes in blood sugar levels?

Yes, official documents report that disturbances in blood glucose have been seen with fluoroquinolones. These disturbances include both periods of hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar).

Q: Why is Ciprofloxacin not routinely used to treat uncomplicated infections in children?

The safety and effectiveness of ciprofloxacin extended-release tablets have generally not been established for pediatric patients (under 18 years). Regulatory restrictions are in place partly due to the potential for musculoskeletal disorders and joint issues (arthropathy) observed in juvenile animals.

Q: How does the once-daily (ОД) dosing schedule support maintaining constant drug levels in the body?

The extended-release formulation is specifically designed to provide sustained concentrations of the active drug in the plasma and urine. This sustained delivery over 24 hours is the basis for the single daily dosing regimen.

Q: What is the defined half-life of Ciprofloxacin, according to pharmacology data?

According to the pharmacology data in the prescribing information, the plasma elimination half-life of ciprofloxacin in healthy volunteers following the extended-release dose is approximately 4.5 hours.

Q: What research evidence supports the efficacy of Цифран ОД for its intended uses?

Official prescribing information confirms that the efficacy of the extended-release product is supported by clinical studies that established the defined clinical and microbiological response rates for the approved indications.

Storage and Disposal Requirements for Ciprofloxacin Extended-Release

Official regulatory labeling dictates specific storage and handling conditions to ensure the stability of Ciprofloxacin Extended-Release Tablets (Цифран ОД).

---

️ Storage Conditions

Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature, 25 C (77 F). Allowed excursions range from 15 C to 30 C (59 F to 86 F).
Container	Must be kept in a well-closed container to protect the product.
Child Safety	Keep out of the reach of children.

---

️ Disposal Instructions

Unused or expired medication should be disposed of according to official protocols. The preferred method is to utilize an authorized medicine take-back program.

If a take-back program is unavailable, unused tablets may be mixed with an undesirable substance (such as dirt or coffee grounds) and placed in a sealed container before discarding in household trash. This procedure prevents the drug from entering the water supply.